GFAP accumulating in stroke

Patent metadata

Field	Value
Publication number	US-12332252-B2
Application number	US-201716462520-A
Country	US
Kind code	B2
Filing date	Nov 20, 2017
Priority date	Nov 23, 2016
Publication date	Jun 17, 2025
Grant date	Jun 17, 2025

Abstract

The disclosure describes the use of glial fibrillary acidic protein as a marker of pernicious stroke.

First claim

The invention claimed is:

1. A method for diagnosis and treatment comprising:
(a) obtaining a first biological sample from a suspected pernicious stroke patient at admission, wherein the patient is admitted <6 hours from symptom onset, wherein the biological sample, is blood, serum or plasma;
(b) measuring a first amount of glial fibrillary acidic protein (GFAP) in the first biological sample;
(c) subjecting the patient to a brain CT scan (CT scan) on admission;
(d) diagnosing the patient as having fatal ischemic stroke or hemorrhagic transformation comprising:
(i) identifying the patient as having fatal ischemic stroke when (1) the first amount of GFAP is at least 2-fold higher than a normal control level, wherein the normal control level is the level of GFAP measured in a population of patients comprising non-fatal ischemic stroke patients or a value within a range of 0.140 ng/ml to 0.205 ng/ml, and (2) the CT scan is negative for hemorrhagic stroke, and
(ii) identifying the patient as having non-fatal ischemic stroke undergoing hemorrhagic transformation when the amount of GFAP in the first sample has the normal control level and the CT scan is negative for hemorrhagic stroke at admission, and the method further comprises measuring a second amount of GFAP in a further biological sample taken from said patient at ≥24 hours from admission or symptom onset, wherein a higher level of the second amount of GFAP in the second sample than the first level of GFAP measured in the patient identified as having fatal ischemic stroke of (i), is indicative of hemorrhagic transformation; and

(e) treating the diagnosed patient of (d) comprising administering a therapy, wherein the therapy for the identified patient of (i) is selected from the group consisting of an anti-thrombolytic therapy, anti-coagulative therapy or combination, and the therapy for the patient of (ii) comprises administering surgical repair of a damaged blood vessel.

2. The method of claim 1 in which the second amount of glial fibrillary acidic protein measurement from said further biological sample is taken at 24-96 hours from admission or from symptom onset.

3. The method of claim 1 in which the first amount of B glial fibrillary acidic protein measurement is taken s 5 hours from symptom onset, wherein the measurement is of the biological sample.

4. The method of claim 1 , wherein the value is between 0.165-0.205 ng/ml.

Assignees

• Randox Laboratories Ltd
• Randox Teoranta

Inventors

• Fitzgerald Stephen Peter
• Mcconnell Ivan
• Richardson Ciaran
• Lamont John
• Makris Konstantinos

Classifications

• G01N2800/2871

  Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event · CPC title

• G16H50/30

  for calculating health indices; for individual health risk assessment · CPC title

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title